the NICE finding
arms.nice.org.uk/resources/hub/1070905/attachment
The summary of the conclusion is
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.
__
This is a report on The Swedish changes - based on lack of evidence.
genderreport.ca/the-swedish-u-turn-on-gender-transitioning/
_
Australia and NZ College of Psychiatrists publish a warning there is not enough evidence.
//www.ranzcp.org/news-policy/policy-and-advocacy/position-statements/gender-dysphoria
The Royal Australian and New Zealand College of Psychiatrists have now updated their guidance.
They are now warning that there is NOT ENOUGH evidence to recommend affirming only treatments or indeed any particular treatment plan. They now say that underlying health issues should be treated at the same time. And warn that medicalisation of children and teens be very careful and thoroughly explored considering the ‘paucity’ of evidence at this time.
Interestingly, they indicate that there are a couple of long term studies under way which will be interesting to see when they are published. One is a longitudinal study on trans patients in Australia.
_
The Cass Review Interim Report - stating there is not enough evidence!
cass.independent-review.uk/wp-content/uploads/2022/03/The-Cass-Review-Interim-Report-Final-Bookmarked.pdf
_
A treasure trove of studies relating to whether there is conclusive improvement to transgender people's lives after medicalised treatment paths can be found in this Medium article by JLCederblom
medium.com/@JLCederblom/the-lukewarm-perjury-of-jack-turban-a85903109051
There is an abridged version as well.
It is actually a run down of the evidence presented by Jack Turban's Declaration in Support of Plaintiff's Motion for a Preliminary Injunction in Brandt et al vs Rutledge et al in the US District Court for the Eastern District of Arkansas.
In it is this review listed as footnote 15. Baker, K. E., et al, (2021) Hormone Therapy, Mental Health and Quality of Life Among Transgender People: A Systematic Review. Journal of the Endocrine Society.
academic.oup.com/jes/article/5/4/bvab011/6126016
I was interested particularly in this finding.
Quality of Life
Among adolescents, a mixed-gender prospective cohort (n = 50) showed no difference in QOL scores after a year of endocrine interventions, which included combinations of GnRH analogues and estrogen or testosterone formulations [30]. No study found that hormone therapy decreased QOL scores. We conclude that hormone therapy may improve QOL among transgender people. The strength of evidence for this conclusion is low due to concerns about bias in study designs, imprecision in measurement because of small sample sizes, and confounding by factors such as gender-affirming surgery status.
And this under Depression
Among adolescents, 2 mixed-gender prospective cohorts (n = 50 and n = 23, respectively) showed improvements in depression scores after 1 year of treatment with GnRH analogues and estrogen or testosterone formulations (both P < 0.001) [30, 38]. Another prospective study reported that BDI scores improved almost by half among adolescents (n = 41) after a mean of 1.88 years of treatment with GnRH analogues to delay puberty (P = 0.004) [34]. The overall improvement after several subsequent years of testosterone or estrogen therapy in this cohort (n = 32) was smaller, however, resulting in no significant change from baseline [35]. No study found that hormone therapy increased depression.
Anxiety
Among adolescents, 1 prospective study saw mean anxiety scores in a mixed-gender group (n = 23) improve from 33.0 ± 7.2 to 18.5 ± 8.4 after 1 year (P < 0.001) [38], but another reported no changes in anxiety after approximately 2 years of puberty delay treatment with GnRH analogues and 4 years of hormone therapy (n = 32) [35].
Suicide
The risk of bias for this study was serious due to the difficulty of identifying appropriate comparison groups and uncontrolled confounding by surgery status and socioeconomic variables such as unemployment. We cannot draw any conclusions on the basis of this single study about whether hormone therapy affects death by suicide among transgender people.
_
think it is a good short explainer on why affirming only is problematic.
www.smh.com.au/national/nsw/now-i-m-hopeful-we-can-we-talk-about-teens-and-gender-20211031-p594q6.html
Now I’m hopeful we can talk about teens and gender
Dr Sandra Pertot
I found this very clear as an explanation
Although there is agreement across all clinicians working with gender-questioning adolescents that they typically report a history of mental health problems, increasingly some clinicians will consider the possibility that the client has come to the belief they are transgender as a way of providing an explanation for and resolving their pre-existing problems. In my experience, gender-affirming therapists strongly disagree, believing that anything other than immediately affirming the client’s expressed belief they are transgender will compound the harm. My view is that it is precisely because of the high rate of mental health problems in this group that a careful and comprehensive mental health assessment is required as a first step. Shepherding all of these vulnerable young people down the same pathway is poor clinical practice.
New FDA warning for Puberty Blockers:
publications.aap.org/aapnews/news/20636/Risk-of-pseudotumor-cerebri-added-to-labeling-for?autologincheck=redirected
The Food and Drug Administration (FDA) has added a warning about the risk of pseudotumor cerebri (idiopathic intracranial hypertension) to the labeling for gonadotropin-releasing hormone (GnRH) agonists that are approved for the treatment of central precocious puberty in pediatric patients. These products include Lupron Depot-Ped (leuprolide acetate), Fensolvi (leuprolide acetate), Synarel (nafarelin), Supprelin LA (histrelin) and Triptodur (triptorelin).
The new warning includes recommendations to monitor patients taking GnRH agonists for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred or loss of vision, diplopia, pain behind the eye or pain with eye movement, tinnitus, dizziness and nausea.
And
Six cases were identified that supported a plausible association between GnRH agonist use and pseudotumor cerebri. All six cases were reported in birth-assigned females ages 5 to 12 years. Five were undergoing treatment for central precocious puberty and one for transgender care. The onset of pseudotumor cerebri symptoms ranged from three to 240 days after GnRH agonist initiation.
Why is this one so important? Because there are still support groups who tell parents that puberty blockers are 'safe and reversible'. Again, misinformation like that is so fucking harmful to children.